Overview

Fexofenadine in Pruritic Skin Disease

Status:
Completed

Trial end date:
2006-10-01

Target enrollment:

Participant gender:

Summary

Primary objective: - To compare the efficacy and safety profile of Fexofenadine 180mg tablets plus prednicarbate(2.5mg/g) vs prednicarbate(2.5mg/g) alone in the treatment of pruritic skin disease Secondary objective: - To evaluate patient's satisfaction of Allegra treatment

Phase:

Phase 4

Details

Lead Sponsor:

Handok Inc.
Handok Pharmaceuticals Co., Ltd.

Treatments:

Fexofenadine
Terfenadine